GTBP faces a high probability of delisting by November 16, 2026, unless the stock price recovers above $1 for 10 consecutive business days. The company has no disclosed reverse-split or capital-raise plan. Traders should expect continued downward pressure and potential OTC transfer. Monitor for any reverse-split announcement or capital infusion as the only realistic path to compliance.
Price Chart
Executive Summary
GT Biopharma received a Nasdaq notice granting an additional 180-day compliance period until November 16, 2026, to regain the $1.00 minimum bid price requirement. The stock has been below $1 since at least November 2025, and the company previously restated financials in March 2026 due to a liability classification error. Delisting risk remains elevated if the bid price does not recover.
Key Facts
- Nasdaq granted an additional 180-day compliance period until November 16, 2026, to meet the $1.00 minimum bid price rule.
- The initial 180-day compliance period (from November 20, 2025) expired on May 19, 2026, without compliance being achieved.
- The company previously restated its Q2 and Q3 2025 financials on March 1, 2026, due to a $28.7M liability classification error on Greenshoe Rights.
- Market cap is approximately $16M, and the stock has been trading below $1 for over six months.
- The company stated it will monitor the bid price and assess options, but gave no specific plan to regain compliance.
Financial Impact
No specific financial impact quantified in the filing. The delisting risk alone threatens Nasdaq listing, which typically reduces institutional ownership and liquidity.
Risk Factors
- Failure to regain $1 bid price by November 16, 2026, will result in Nasdaq delisting and transfer to OTC markets.
- The March 2026 restatement signals accounting control weaknesses, which may complicate any capital raise or reverse-split approval.
- No specific compliance plan has been disclosed, increasing uncertainty around the timeline.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-024913 |
| Document: 0001493152-26-024913-index-headers.html | 0001493152-26-024913 |
| Document: 0001493152-26-024913-index.html | 0001493152-26-024913 |
| Document: 0001493152-26-024913.txt | 0001493152-26-024913 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $9.00 $7.16 | ▲ +20.44% | ▲ +21.26% | $6.10 (+32.22%) |
Sep 3, 2026 29d ago | 8-K | $0.2524 $8.61 | ▲ +3311.25% | ▲ +3312.40% | $6.10 (+2316.80%) |
Aug 14, 2026 7w ago | Press Release | $0.2960 $0.2886 | ▲ +2.50% | ▲ +1.13% | $6.10 (−1960.81%) |
May 22, 2026 19w ago | 8-K | $0.4400 $0.4420 | ▼ −0.45% | ▲ +1.22% | $6.10 (−1286.36%) |
Apr 30, 2026 22w ago | S-1 | $0.3430 $0.3750 | ▼ −9.33% | ▼ −6.98% | $6.10 (−1678.43%) |
Apr 7, 2026 25w ago | 8-K | $0.4130 $0.3890 | ▼ −5.81% | ▼ −11.14% | $6.10 (+1377.00%) |
Mar 2, 2026 30w ago | Press Release | $0.4670 $0.4170 | ▼ −10.71% | ▼ −9.50% | $6.10 (+1206.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access